Veeva Announces New Mobile and AI Innovations in Veeva CRM
14.5.2019 14:03:00 EEST | Business Wire | Press release
Veeva Systems (NYSE:VEEV) today announced two new innovations in Veeva CRM that continue to advance compliance and digital engagement in the life sciences industry. Veeva CRM Approved Notes makes it easy for field reps to capture free text notes in Veeva CRM and leverage the power of artificial intelligence (AI) to save information without risk. Veeva Approved Messaging will add support for messaging applications such as WeChat and WhatsApp to open up new digital channels for compliant engagement.
These latest innovations build upon Veeva’s continued investment in the industry’s leading CRM platform, including Veeva CRM’s real-time architecture to ensure field reps can access CRM details when and where they need them from any device.
“We continue to deliver industry-first capabilities that help companies provide the best customer experience with Veeva CRM,” said David Logue, senior vice president of commercial strategy at Veeva Europe. “With rich note-taking in Veeva CRM Approved Notes and the ability for reps to send personalized messages with Veeva CRM Approved Messaging, organizations can build better customer relationships and remain compliant with every interaction.”
Veeva is advancing the industry’s efficiency and effectiveness with the following innovative capabilities in Veeva CRM:
- Veeva CRM Approved Notes will be a new capability included in Veeva CRM that allows field reps to compliantly capture detailed notes of customer interactions. AI in Veeva CRM will help automatically detect potential compliance risks such as off-label messaging. With the freedom and flexibility to capture rich notes, reps can build stronger relationships and drive smarter, more informed customer interactions with lower risk. Veeva Approved Notes is planned for availability in 2020.
- Veeva CRM Approved Messaging will open up new digital channels for reps to engage in relevant, timely interactions with healthcare professionals. Companies can use messaging applications, including WhatsApp and WeChat, to send compliant messages to customers through any mobile device. Messaging now gives reps another digital channel to reach and engage HCPs and drive a personalized customer experience. Veeva Approved Messaging is available today for WeChat. Availability for WhatsApp is planned for 2020.
- Veeva CRM’s real-time architecture and Autosync capability will ensure all information is consistent across all devices. Activity, customer, and product data will automatically synchronize and always be available from any Apple and Windows phone, tablet, and laptop. With advanced mobile innovations in Veeva CRM, field teams can access the information they need for improved execution and productivity. Veeva CRM’s Autosync is planned for availability in August 2019. See our infographic to learn how Veeva CRM is enabling real-time reps to do more from any device, anywhere.
Veeva helps customers stay current with the most recent enhancements from leading platform and operating system providers. Looking ahead, Veeva CRM will leverage the latest innovations from Apple, Microsoft, and Salesforce. Planned for availability in 2020, Veeva CRM will work with Apple touch ID and face ID to make it fast and easy for field reps to securely log in and open their CRM application. Veeva CRM’s Sunrise user interface is now available on Windows 10 devices to provide a consistent and intuitive mobile experience for Windows users across all devices. And Veeva CRM is expected to be Lightning ready by the end of 2019 so customers can leverage Salesforce’s new user interface for online browsers.
In other news today, Veeva introduced Veeva Andi, a new AI application as part of the Veeva CRM Suite that embeds tailored insights and suggestions right in Veeva CRM. Veeva also announced new capabilities in Veeva Commercial Cloud, including Veeva Vault Auto Claims Linking in Veeva Vault PromoMats to help improve speed and compliance of content development. Read today’s Veeva Andi press release and Veeva Commercial Cloud press release to learn more.
Registrations for Veeva Commercial & Medical Summit Europe are now open. Join us in Barcelona from 3-5 December 2019, where more than 1,200 life sciences professionals will gather to hear the latest news and market trends in the industry, experience innovative technology, and network and share best practices.
Additional Information
For more information on Veeva CRM, visit: veeva.com/eu/CRM
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veeva_eu on Twitter: twitter.com/veeva_eu
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005486/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom